Citations (59)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Raffaella Zanardi, Dario Prestifilippo, Chiara Fabbri, Cristina Colombo, Eduard Maron & Alessandro Serretti. (2021) Precision psychiatry in clinical practice. International Journal of Psychiatry in Clinical Practice 25:1, pages 19-27.
Read now
Read now
Cristina Mora, Valentina Zonca, Marco A. Riva & Annamaria Cattaneo. (2018) Blood biomarkers and treatment response in major depression. Expert Review of Molecular Diagnostics 18:6, pages 513-529.
Read now
Read now
Chiara Fabbri, Ladislav Hosak, Rainald Mössner, Ina Giegling, Laura Mandelli, Frank Bellivier, Stephan Claes, David A. Collier, Alejo Corrales, Lynn E. Delisi, Carla Gallo, Michael Gill, James L. Kennedy, Marion Leboyer, Amanda Lisoway, Wolfgang Maier, Miguel Marquez, Isabelle Massat, Ole Mors, Pierandrea Muglia, Markus M. Nöthen, Michael C. O’Donovan, Jorge Ospina-Duque, Peter Propping, Yongyong Shi, David St Clair, Florence Thibaut, Sven Cichon, Julien Mendlewicz, Dan Rujescu & Alessandro Serretti. (2017) Consensus paper of the WFSBP Task Force on Genetics: Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response. The World Journal of Biological Psychiatry 18:1, pages 5-28.
Read now
Read now
Chiara Fabbri, Concetta Crisafulli, Marco Calabrò, Edoardo Spina & Alessandro Serretti. (2016) Progress and prospects in pharmacogenetics of antidepressant drugs. Expert Opinion on Drug Metabolism & Toxicology 12:10, pages 1157-1168.
Read now
Read now
Kristina Probst-Schendzielorz, Roberto Viviani & Julia C Stingl. (2015) Effect of Cytochrome P450 polymorphism on the action and metabolism of selective serotonin reuptake inhibitors. Expert Opinion on Drug Metabolism & Toxicology 11:8, pages 1219-1232.
Read now
Read now
Chiara Fabbri, Alessandro Minarini, Tomihisa Niitsu & Alessandro Serretti. (2014) Understanding the pharmacogenetics of selective serotonin reuptake inhibitors. Expert Opinion on Drug Metabolism & Toxicology 10:8, pages 1093-1118.
Read now
Read now
Daniel J. Müller, Ivana Kekin, Amy C. C. Kao & Eva J. Brandl. (2013) Towards the implementation of CYP2D6 and CYP2C19 genotypes in clinical practice: Update and report from a pharmacogenetic service clinic. International Review of Psychiatry 25:5, pages 554-571.
Read now
Read now
Pothitos M Pitychoutis, Nikolaos Kokras, Despina Sanoudou, Christina Dalla & Zeta Papadopoulou-Daifoti. (2013) Pharmacogenetic considerations for late life depression therapy. Expert Opinion on Drug Metabolism & Toxicology 9:8, pages 989-999.
Read now
Read now
Articles from other publishers (51)
Bashir B. El-Khoury, Kristi L. Ray, Steven I. Altchuler, John F. Reichard & Charles H. Dukes. (2023) Selective Serotonin Reuptake Inhibitors and Other Treatment Modalities for Deep Space Missions. Aerospace Medicine and Human Performance 94:11, pages 843-851.
Crossref
Crossref
Sophie E. ter Hark, Cornelis F. Vos, Rob E. Aarnoutse, Aart H. Schene, Marieke J.H. Coenen & Joost G.E. Janzing. (2022) Biomarkers as predictors of treatment response to tricyclic antidepressants in major depressive disorder: A systematic review. Journal of Psychiatric Research 150, pages 202-213.
Crossref
Crossref
A. C. Pronk, L. J. Seppala, K. Trajanoska, N. Stringa, B. van de Loo, L. C. P. G. M. de Groot, N. M. van Schoor, F. Koskeridis, G. Markozannes, E. Ntzani, A. G. Uitterlinden, F. Rivadeneira, B. H. Stricker & N. van der Velde. (2022) Candidate genetic variants and antidepressant-related fall risk in middle-aged and older adults. PLOS ONE 17:4, pages e0266590.
Crossref
Crossref
Alessandro Serretti. (2022) Precision medicine in mood disorders. Psychiatry and Clinical Neurosciences Reports 1:1.
Crossref
Crossref
Leandro Piedimonte & Daniela Flores Helguero. (2021) Psicotrópicos y FarmacogenéticaPsychotropics and Pharmacogenetics. NeuroTarget 14:2, pages 29-51.
Crossref
Crossref
John Papastergiou, Lena C. Quilty, Wilson Li, Thulasi Thiruchselvam, Esha Jain, Peter Gove, Leilany Mandlsohn, Bart den Bemt & Nedzad Pojskic. (2021) Pharmacogenomics guided versus standard antidepressant treatment in a community pharmacy setting: A randomized controlled trial. Clinical and Translational Science 14:4, pages 1359-1368.
Crossref
Crossref
Benjamin Laplace, Benjamin Calvet, Aurelie Lacroix, Stephane Mouchabac, Nicolas Picard, Murielle Girard & Eric Charles. (2021) Acceptability of Pharmacogenetic Testing among French Psychiatrists, a National Survey. Journal of Personalized Medicine 11:6, pages 446.
Crossref
Crossref
Farhana Islam, Ilona Gorbovskaya & Daniel J. Müller. 2021. Major Depressive Disorder. Major Depressive Disorder
231
255
.
Chiara Fabbri & Alessandro Serretti. (2020) How to Utilize Clinical and Genetic Information for Personalized Treatment of Major Depressive Disorder: Step by Step Strategic Approach. Clinical Psychopharmacology and Neuroscience 18:4, pages 484-492.
Crossref
Crossref
Christoph Linnemann & Undine E. Lang. (2020) Pathways Connecting Late-Life Depression and Dementia. Frontiers in Pharmacology 11.
Crossref
Crossref
Chiara Fabbri & Alessandro Serretti. (2020) Genetics of Treatment Outcomes in Major Depressive Disorder: Present and Future. Clinical Psychopharmacology and Neuroscience 18:1, pages 1-9.
Crossref
Crossref
Shivakumar Kolachalam, Stefano Aringhieri & Marco Scarselli. 2019. Brain and Heart Dynamics. Brain and Heart Dynamics
1
11
.
Shivakumar Kolachalam, Stefano Aringhieri & Marco Scarselli. 2020. Brain and Heart Dynamics. Brain and Heart Dynamics
753
763
.
Prasad Shetty. (2016) Pharmacogenomics and its Future Implications in Treatment-resistant Depression. Indian Journal of Private Psychiatry 13:2, pages 71-76.
Crossref
Crossref
Filippo Corponi, Chiara Fabbri & Alessandro Serretti. (2019) Pharmacogenetics and Depression: A Critical Perspective. Psychiatry Investigation 16:9, pages 645-653.
Crossref
Crossref
Domenico De Donatis, Vincenzo Florio, Stefano Porcelli, Alois Saria, Laura Mercolini, Alessandro Serretti & Andreas Conca. (2019) Duloxetine plasma level and antidepressant response. Progress in Neuro-Psychopharmacology and Biological Psychiatry 92, pages 127-132.
Crossref
Crossref
Yuhao Zhu, Naixing Zhang, Decheng Ren, Yan Bi, Fei Xu, Weibo Niu, Qianqian Sun, Zhenming Guo, Ruixue Yuan, Fan Yuan, Xi Wu, Yanfei Cao, Fengping Yang, Lu Wang, Li Du, Weidong Li, Yifeng Xu, Xingwang Li, Liping Zhu, Lin He, Lei Shi, Guang He & Tao Yu. (2019) CYP1A2 Genetic Polymorphism Is Associated With Treatment Remission to Antidepressant Venlafaxine in Han Chinese Population. Clinical Neuropharmacology 42:2, pages 32-36.
Crossref
Crossref
Qianqian He, Yan Mei, Yuanyuan Liu, Zhuo Yuan, Jian Zhang, Hong Yan, Li Shen & Yong Zhang. (2019) Effects of Cytochrome P450 2C19 Genetic Polymorphisms on Responses to Escitalopram and Levels of Brain-Derived Neurotrophic Factor in Patients With Panic Disorder. Journal of Clinical Psychopharmacology 39:2, pages 117-123.
Crossref
Crossref
Haley V. Solomon, Kevin W. Cates & Kevin J. Li. (2019) Does obtaining CYP2D6 and CYP2C19 pharmacogenetic testing predict antidepressant response or adverse drug reactions?. Psychiatry Research 271, pages 604-613.
Crossref
Crossref
Chiara Fabbri, Katherine E. Tansey, Roy H. Perlis, Joanna Hauser, Neven Henigsberg, Wolfgang Maier, Ole Mors, Anna Placentino, Marcella Rietschel, Daniel Souery, Gerome Breen, Charles Curtis, Sang-Hyuk Lee, Stephen Newhouse, Hamel Patel, Michael O'Donovan, Glyn Lewis, Gregory Jenkins, Richard M. Weinshilboum, Anne Farmer, Katherine J. Aitchison, Ian Craig, Peter McGuffin, Koen Schruers, Joanna M. Biernacka, Rudolf Uher & Cathryn M. Lewis. (2018) Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: Meta-analysis of data from genome-wide association studies. European Neuropsychopharmacology 28:8, pages 945-954.
Crossref
Crossref
Bharathi S. Gadad, Manish K. Jha, Andrew Czysz, Jennifer L. Furman, Taryn L. Mayes, Michael P. Emslie & Madhukar H. Trivedi. (2018) Peripheral biomarkers of major depression and antidepressant treatment response: Current knowledge and future outlooks. Journal of Affective Disorders 233, pages 3-14.
Crossref
Crossref
Joseph R. Boland, Brenna Duffy & Nicole M. Myer. (2018) Clinical utility of pharmacogenetics-guided treatment of depression and anxiety. Personalized Medicine in Psychiatry 7-8, pages 7-13.
Crossref
Crossref
Alessandro Serretti. (2018) The Present and Future of Precision Medicine in Psychiatry: Focus on Clinical Psychopharmacology of Antidepressants. Clinical Psychopharmacology and Neuroscience 16:1, pages 1-6.
Crossref
Crossref
Filippo Corponi, Chiara Fabbri & Alessandro Serretti. 2018. Pharmacogenetics. Pharmacogenetics
297
331
.
Chiara Fabbri & Alessandro Serretti. 2018. Understanding Depression. Understanding Depression
3
16
.
Vincenzo Florio, Stefano Porcelli, Alois Saria, Alessandro Serretti & Andreas Conca. (2017) Escitalopram plasma levels and antidepressant response. European Neuropsychopharmacology 27:9, pages 940-944.
Crossref
Crossref
Marzia Del Re, Stefano Fogli, Lisa Derosa, Francesco Massari, Paul De Souza, Stefania Crucitta, Sergio Bracarda, Daniele Santini & Romano Danesi. (2017) The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide. Cancer Treatment Reviews 55, pages 71-82.
Crossref
Crossref
Wei Qi, Martin Gevonden & Arieh Shalev. (2017) Efficacy and Tolerability of High-Dose Escitalopram in Posttraumatic Stress Disorder. Journal of Clinical Psychopharmacology 37:1, pages 89-93.
Crossref
Crossref
Chiara Fabbri & Alessandro Serretti. 2016. Genetic Influences on Response to Drug Treatment for Major Psychiatric Disorders. Genetic Influences on Response to Drug Treatment for Major Psychiatric Disorders
39
54
.
Alessandro Serretti & Chiara Fabbri. 2016. Pharmacovigilance in Psychiatry. Pharmacovigilance in Psychiatry
121
146
.
Virginie Y. Martiny, Pablo Carbonell, Florent Chevillard, Gautier Moroy, Arnaud B. Nicot, Philippe Vayer, Bruno O. Villoutreix & Maria A. Miteva. (2015)
Integrated structure- and ligand-based
in silico
approach to predict inhibition of cytochrome P450 2D6
. Bioinformatics 31:24, pages 3930-3937.
Crossref
Crossref
Chiara Fabbri & Alessandro Serretti. (2015) Pharmacogenetics of Major Depressive Disorder: Top Genes and Pathways Toward Clinical Applications. Current Psychiatry Reports 17:7.
Crossref
Crossref
Edoardo Spina & Jose de Leon. (2014) Clinical applications of CYP genotyping in psychiatry. Journal of Neural Transmission 122:1, pages 5-28.
Crossref
Crossref
Yoshihiko Matsumoto, Chiara Fabbri, Silvia Pellegrini, Stefano Porcelli, Pierluigi Politi, Silvio Bellino, Caterina Iofrida, Veronica Mariotti, Erika Melissari, Marco Menchetti, Valentina Martinelli, Marco Cappucciati, Paola Bozzatello, Elena Brignolo, Paolo Brambilla, Matteo Balestrieri & Alessandro Serretti. (2014) Serotonin Transporter Gene: A New Polymorphism May Affect Response to Antidepressant Treatments in Major Depressive Disorder. Molecular Diagnosis & Therapy 18:5, pages 567-577.
Crossref
Crossref
Olivia F. O'Leary, Fionn E. O'Brien, Richard M. O'Connor & John F. Cryan. (2014) Drugs, genes and the blues: Pharmacogenetics of the antidepressant response from mouse to man. Pharmacology Biochemistry and Behavior 123, pages 55-76.
Crossref
Crossref
Barbara Breitenstein, Sandra Scheuer & Florian Holsboer. (2014) Are there meaningful biomarkers of treatment response for depression?. Drug Discovery Today 19:5, pages 539-561.
Crossref
Crossref
Pierre BaumannPierre Baumann. 2014. CYP2D6: Genetics, Pharmacology and Clinical Relevance. CYP2D6: Genetics, Pharmacology and Clinical Relevance
134
150
.
Chiara Fabbri, Stefano Porcelli & Alessandro Serretti. (2014) From Pharmacogenetics to Pharmacogenomics: The Way toward the Personalization of Antidepressant Treatment. The Canadian Journal of Psychiatry 59:2, pages 62-75.
Crossref
Crossref
Chiara Fabbri, Alessandro Minarini, Yoshihiko Matsumoto & Alessandro Serretti. 2014. Handbook of Pharmacogenomics and Stratified Medicine. Handbook of Pharmacogenomics and Stratified Medicine
543
562
.
Vladimir S. Naumenko, Daria V. Bazovkina, Alina A. Semenova, Anton S. Tsybko, Tatyana V. Il'chibaeva, Elena M. Kondaurova & Nina K. Popova. (2013) Effect of glial cell line-derived neurotrophic factor on behavior and key members of the brain serotonin system in mouse strains genetically predisposed to behavioral disorders. Journal of Neuroscience Research 91:12, pages 1628-1638.
Crossref
Crossref
Virginie Y. Martiny & Maria A. Miteva. (2013) Advances in Molecular Modeling of Human Cytochrome P450 Polymorphism. Journal of Molecular Biology 425:21, pages 3978-3992.
Crossref
Crossref
Chiara Fabbri, Agnese Marsano, Martina Balestri, Diana De Ronchi & Alessandro Serretti. (2013) Clinical features and drug induced side effects in early versus late antidepressant responders. Journal of Psychiatric Research 47:10, pages 1309-1318.
Crossref
Crossref
Chiara Fabbri, Giulia Di Girolamo & Alessandro Serretti. (2013) Pharmacogenetics of antidepressant drugs: An update after almost 20 years of research. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 162:6, pages 487-520.
Crossref
Crossref
Peter Höfer, Alexandra Schosser, Raffaella Calati, Alessandro Serretti, Isabelle Massat, Neslihan Aygun Kocabas, Anastasios Konstantinidis, Sylvie Linotte, Julien Mendlewicz, Daniel Souery, Joseph Zohar, Alzbeta Juven-Wetzler, Stuart Montgomery & Siegfried Kasper. (2012) The impact of Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes on suicide attempt and suicide risk—a European multicentre study on treatment-resistant major depressive disorder. European Archives of Psychiatry and Clinical Neuroscience 263:5, pages 385-391.
Crossref
Crossref
Siegfried Kasper & Stuart MontgomeryChiara Fabbri, Stefano Porcelli & Alessandro Serretti. 2013. Treatment‐resistant Depression. Treatment‐resistant Depression
43
90
.
Cristina LorenziAdele Pirovano & Marta Bosia. (2013) Research Highlights: Highlights from the latest research in mood disorder pharmacogenomics. Pharmacogenomics 14:2, pages 127-130.
Crossref
Crossref
Amanda L. Mitsch. (2013) Antidepressant adverse drug reactions in older adults: Implications for RNs and APNs. Geriatric Nursing 34:1, pages 53-61.
Crossref
Crossref
Ross J. BaldessariniRoss J. Baldessarini. 2013. Chemotherapy in Psychiatry. Chemotherapy in Psychiatry
155
250
.
Ana Blazquez, Sergi Mas, Ma Teresa Plana, Amàlia Lafuente & Luisa Lázaro. (2012) Fluoxetine pharmacogenetics in child and adult populations. European Child & Adolescent Psychiatry 21:11, pages 599-610.
Crossref
Crossref
Teresa L. Dzieweczynski & Olivia L. Hebert. (2012) Fluoxetine alters behavioral consistency of aggression and courtship in male Siamese fighting fish, Betta splendens. Physiology & Behavior 107:1, pages 92-97.
Crossref
Crossref
Carlos A. ZarateJr.Jr., Nancy Brutsche, Gonzalo Laje, David A. Luckenbaugh, Swarajya L. Vattem Venkata, Anuradha Ramamoorthy, Ruin Moaddel & Irving W. Wainer. (2012) Relationship of Ketamine's Plasma Metabolites with Response, Diagnosis, and Side Effects in Major Depression. Biological Psychiatry 72:4, pages 331-338.
Crossref
Crossref